Kane Biotech Inc (KNE.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 19 | 32 | 36 | 46 | 48 |
| Income taxes - deferred | 4 | N/A | N/A | N/A | N/A |
| Accounts receivable | 7 | 95 | 8 | 65 | -116 |
| Other Working Capital | 143 | -248 | -149 | -345 | -135 |
| Other Operating Activity | -659 | -559 | -593 | -539 | -901 |
| Operating Cash Flow | $-486 | $-681 | $-698 | $-773 | $-1,104 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | 0 | 60 | 9 | -14 |
| Purchase Sale Intangibles | -13 | -22 | -6 | -50 | -31 |
| Investing Cash Flow | $-13 | $-22 | $54 | $-41 | $-45 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 1,000 | N/A |
| Debt Issued | N/A | -28 | N/A | N/A | N/A |
| Debt Repayment | -6 | -18 | -21 | -113 | -155 |
| Common Stock Issued | 0 | 689 | 0 | 1,086 | 1,451 |
| Other Financing Activity | -2 | 21 | -9 | -40 | -13 |
| Financing Cash Flow | $-8 | $665 | $-30 | $1,933 | $1,283 |
| Beginning Cash Position | 902 | 939 | 1,613 | 494 | 359 |
| End Cash Position | 395 | 902 | 939 | 1,613 | 494 |
| Net Cash Flow | $-507 | $-37 | $-674 | $1,119 | $135 |
| Free Cash Flow | |||||
| Operating Cash Flow | -486 | -681 | -698 | -773 | -1,104 |
| Capital Expenditure | -13 | -22 | -6 | -50 | -45 |
| Free Cash Flow | -499 | -703 | -704 | -823 | -1,149 |